Cypher Sales In Japan Help Cordis Achieve 19% Revenue Jump In 2004
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's Cordis unit grew its top line 19% to $3.21 bil. in 2004, due in part to robust Cypher sirolimus-eluting stent sales in Japan, CEO William Weldon stated in a Jan. 25 earnings call
You may also be interested in...
Taxus Will Continue To Lead Coronary Stent Market, Boston Scientific Vows
Boston Scientific aspires to retain the number-one position in the coronary stent space over the next few years by consistently bringing next-generation products to market ahead of competitors
Taxus Will Continue To Lead Coronary Stent Market, Boston Scientific Vows
Boston Scientific aspires to retain the number-one position in the coronary stent space over the next few years by consistently bringing next-generation products to market ahead of competitors
Cordis Recalls 300 Underweight Cypher Units, Predicts Zero Adverse Events
Johnson & Johnson/Cordis' 300-unit recall of its Cypher sirolimus-eluting stent from 145 centers nationwide marks the most recent manufacturing glitch for the high-profile sector